[go: up one dir, main page]

IL58673A - Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same - Google Patents

Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same

Info

Publication number
IL58673A
IL58673A IL58673A IL5867379A IL58673A IL 58673 A IL58673 A IL 58673A IL 58673 A IL58673 A IL 58673A IL 5867379 A IL5867379 A IL 5867379A IL 58673 A IL58673 A IL 58673A
Authority
IL
Israel
Prior art keywords
isolation
membrane proteins
neisseria meningitidis
containing same
vaccines containing
Prior art date
Application number
IL58673A
Other versions
IL58673A0 (en
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of IL58673A0 publication Critical patent/IL58673A0/en
Publication of IL58673A publication Critical patent/IL58673A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Process for the isolation of membrane proteins from Neisseria meningitidis which comprises treating the organism with the aqueous solution of a detergent in a concentration of 0.1 to 2% w/v for 15 minutes to 24 hours, allowing the mixture to stand, optionally with agitation, separating the extract from the bacterial residue and optionally carrying out a further purification.
IL58673A 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same IL58673A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782848965 DE2848965A1 (en) 1978-11-11 1978-11-11 METHOD FOR PRODUCING MEMBRANE PROTEINS FROM NEISSERIA MENINGITIDIS AND VACCINE CONTAINING THEM

Publications (2)

Publication Number Publication Date
IL58673A0 IL58673A0 (en) 1980-02-29
IL58673A true IL58673A (en) 1983-02-23

Family

ID=6054405

Family Applications (1)

Application Number Title Priority Date Filing Date
IL58673A IL58673A (en) 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same

Country Status (9)

Country Link
EP (1) EP0011243B1 (en)
JP (1) JPS5566519A (en)
AT (1) ATE857T1 (en)
AU (1) AU533386B2 (en)
CA (1) CA1142083A (en)
DE (2) DE2848965A1 (en)
DK (1) DK154841C (en)
ES (1) ES485715A1 (en)
IL (1) IL58673A (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127681B1 (en) * 1982-12-02 1993-03-03 The Rockefeller University Iga binding protein
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
DE69934225T2 (en) 1998-05-29 2007-09-27 Novartis Vaccines and Diagnostics, Inc., Emeryville COMBINED MENINGITIS B / C VACCINES
EP2270174A1 (en) 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ES2588917T3 (en) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa VME supplement supplemented against meningococcus
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
MY149591A (en) 2002-08-02 2013-09-13 Glaxosmithkline Biolog Sa Vaccines comprising l2 and/or l3 los from neisseria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CU23313A1 (en) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia MÃ0 / 00 METHOD OF OBTAINING COCLEAR STRUCTURES VACCINAL COMPOSITIONS AND ADJUSTS BASED ON COCLEAR STRUCTURES AND THEIR INTERMEDIARIES
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
JP5173194B2 (en) * 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US20090246224A1 (en) 2006-06-12 2009-10-01 Nathalie Devos Vaccine
MX340096B (en) 2007-10-19 2016-06-27 Glaxosmithkline Biologicals Sa Meningococcal vaccine formulations.
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CA2747340A1 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
CN102740882A (en) 2009-08-27 2012-10-17 诺华有限公司 Adjuvant comprising aluminium, oligonucleotide and polycation
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
JO3257B1 (en) 2009-09-02 2018-09-16 Novartis Ag Vehicles and installations as TLR
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
JP5960055B2 (en) 2009-10-27 2016-08-02 ノバルティス アーゲー Modified meningococcal fHBP polypeptide
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
CN102869377A (en) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 Immunogenic composition
EP2547357A1 (en) 2010-03-18 2013-01-23 Novartis AG Adjuvanted vaccines for serogroup b meningococcus
KR101853513B1 (en) 2010-03-23 2018-04-30 노파르티스 아게 Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
RU2014135522A (en) 2012-02-02 2016-03-27 Новартис Аг Promoters for Enhanced Protein Expression at Meningococcus
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
CN104602704B (en) 2012-06-14 2019-08-06 诺华股份有限公司 Vaccines against serogroup X meningococcus
MX2015002717A (en) 2012-09-06 2015-05-15 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p.
WO2014044728A1 (en) 2012-09-18 2014-03-27 Novartis Ag Outer membrane vesicles
KR20160127104A (en) 2014-02-28 2016-11-02 글락소스미스클라인 바이오로지칼즈 에스.에이. Modified meningococcal fhbp polypeptides
AU2017321039B2 (en) 2016-09-02 2021-03-18 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
CA3075268A1 (en) 2017-09-08 2019-03-14 Evelo Biosciences, Inc. Bacterial extracellular vesicles
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
AU2019376832B2 (en) 2018-11-06 2024-01-25 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202115072D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Also Published As

Publication number Publication date
DK154841B (en) 1988-12-27
EP0011243A1 (en) 1980-05-28
AU533386B2 (en) 1983-11-24
DE2962526D1 (en) 1982-05-27
CA1142083A (en) 1983-03-01
DE2848965A1 (en) 1980-05-22
ATE857T1 (en) 1982-04-15
DK154841C (en) 1989-06-05
IL58673A0 (en) 1980-02-29
EP0011243B1 (en) 1982-04-14
JPS5566519A (en) 1980-05-20
AU5268279A (en) 1980-05-15
DK475779A (en) 1980-05-12
JPS6350332B2 (en) 1988-10-07
ES485715A1 (en) 1980-05-16

Similar Documents

Publication Publication Date Title
DE2962526D1 (en) Process for preparing membrane proteins from neisseria meningitidis and vaccines containing them
DE69423383D1 (en) Production and uses of LOS-reduced outer membrane proteins from gram-negative cocci
ATE195420T1 (en) METHOD FOR PRODUCING EICOSAPENTORIC ACIDS
DE69224124D1 (en) Process for the preparation of dihomo-gamma-linolenic acid and the lipid contained therein
JPS5750925A (en) Preparation of pertussis toxoid
GR3003351T3 (en) Process for preparing a whey product with reduced allergenicity
HUT50863A (en) Amperometric process for quantitative statement of 1,4 dihydronicotinamid adenin dinucleotid /nadh/ in solution
ATE109823T1 (en) MALOLACTIC FERMENTATION OF WINE.
JPS6452726A (en) Method for removing endotoxin of pertussis, pertussis toxoid and production thereof
HUT44422A (en) Method and apparatus for improving the quality of roasted coffee
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
EP0607593A3 (en) Process for obtaining cell cultures with a higher content of autologous cytonines.
ATE72756T1 (en) PROCESS FOR PRODUCTION OF A BIOLOGICAL SUBSTANCE.
AT384032B (en) METHOD FOR PRODUCING POLYDISPERSE NATIVE PSEUDOMONAS-FLAGELLA (H) -ANTIGENS (FAG)
YU45458B (en) Process for obtaining liquid ethanole extract of propolis
DE3366707D1 (en) Preparation of glucose dehydrogenase
JPS57122792A (en) Preparation of cholesterol oxidase
MA21382A1 (en) PROCESS FOR THE PREPARATION OF A JASMINE EXTRACT AND EXTRACT OBTAINED.
FR2429765A1 (en) ADSORPTION PROCESS AND AGENT FOR ISOLATING ENZYMES AND FOR PREPARING THEM IN PURE CONDITIONS
JPS5550890A (en) Preparation of n-acylneuraminic acid aldolase
DE3887713D1 (en) Phenanthridine derivatives, process for their preparation and agents for carrying out the process.
GB2018755A (en) Benzylidene esters
JPS6410950A (en) Elimination of taste and odor of substance rich in amino acid
UA14449A1 (en) Process for preparation of pantocrine
JPS5682095A (en) Purification of fatty acid produced through fermentation process

Legal Events

Date Code Title Description
HP Change in proprietorship
KB Patent renewed